Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Koh, Kwang Kon | - |
dc.contributor.author | Quon, Michael J. | - |
dc.contributor.author | Sakuma, Ichiro | - |
dc.contributor.author | Han, Seung Hwan | - |
dc.contributor.author | Choi, Hanul | - |
dc.contributor.author | Lee, Kyounghoon | - |
dc.contributor.author | Shin, Eak Kyun | - |
dc.date.available | 2020-02-28T23:44:54Z | - |
dc.date.created | 2020-02-06 | - |
dc.date.issued | 2013-06-20 | - |
dc.identifier.issn | 0167-5273 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/14469 | - |
dc.description.abstract | Background: Rosuvastatin and pravastatin have differential hydrophilicity and potency to inhibit hydroxymethylglutaryl-CoA reductase that may be relevant to changes in adiponectin levels, insulin resistance, and the rate of new onset diabetes in large clinical studies. Therefore, we hypothesized that rosuvastatin and pravastatin may have differential metabolic effects in hypercholesterolemic patients. Methods: This was a randomized, single-blind, placebo-controlled, parallel study. Age, gender, and body mass index were matched. Fifty-four patients were given placebo, rosuvastatin 10 mg, or pravastatin 40 mg, respectively once daily for 2 months. Results: When compared with pravastatin therapy, rosuvastatin therapy significantly reduced total, LDL cholesterol, and apolipoprotein B levels (P<0.05 by post-hoc comparison), but comparably improved flow-mediated dilation after 2 months. Interestingly, rosuvastatin therapy significantly increased fasting insulin (mean % changes; 28%, P=0.005). and HbA1c (1%, P=0.038) while decreasing plasma adiponectin levels (9%, P=0.010) and insulin sensitivity (assessed by QUICKI; 2%, P=0.007) when compared with baseline. By contrast, pravastatin therapy significantly decreased fasting insulin (8%, P=0.042), and HbA1c levels (1%, P=0.019) while increasing plasma adiponectin levels (36%, P=0.006) and insulin sensitivity (3%, P=0.005) when compared with baseline. Moreover, these differential effects were evident when outcomes of rosuvastatin and pravastatin therapy were directly compared (P=0.002 for insulin levels by ANOVA on Ranks, P=0.003 for adiponectin, P=0.003 for QUICKI, and P=0.010 for HbA1c by ANOVA). Conclusions: While significantly reducing lipoprotein profiles, rosuvastatin therapy had unwanted metabolic effects in hypercholesterolemic patients when compared with pravastatin therapy, that may be clinically relevant in patients prone to metabolic diseases. (C) 2011 Elsevier Ireland Ltd. All rights reserved. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | ELSEVIER IRELAND LTD | - |
dc.relation.isPartOf | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.subject | ASSESSING INSULIN SENSITIVITY | - |
dc.subject | RECIPROCAL RELATIONSHIPS | - |
dc.subject | CARDIOVASCULAR-DISEASE | - |
dc.subject | GLUCOSE-TOLERANCE | - |
dc.subject | STATIN THERAPY | - |
dc.subject | ADIPONECTIN | - |
dc.subject | ATORVASTATIN | - |
dc.subject | SIMVASTATIN | - |
dc.subject | RESISTANCE | - |
dc.subject | RISK | - |
dc.title | Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.description.journalClass | 1 | - |
dc.identifier.wosid | 000319510200045 | - |
dc.identifier.doi | 10.1016/j.ijcard.2011.11.028 | - |
dc.identifier.bibliographicCitation | INTERNATIONAL JOURNAL OF CARDIOLOGY, v.166, no.2, pp.509 - 515 | - |
dc.identifier.scopusid | 2-s2.0-84878018287 | - |
dc.citation.endPage | 515 | - |
dc.citation.startPage | 509 | - |
dc.citation.title | INTERNATIONAL JOURNAL OF CARDIOLOGY | - |
dc.citation.volume | 166 | - |
dc.citation.number | 2 | - |
dc.contributor.affiliatedAuthor | Koh, Kwang Kon | - |
dc.contributor.affiliatedAuthor | Han, Seung Hwan | - |
dc.contributor.affiliatedAuthor | Choi, Hanul | - |
dc.contributor.affiliatedAuthor | Lee, Kyounghoon | - |
dc.contributor.affiliatedAuthor | Shin, Eak Kyun | - |
dc.type.docType | Article | - |
dc.subject.keywordAuthor | Statins | - |
dc.subject.keywordAuthor | Adiponectin | - |
dc.subject.keywordAuthor | Glycated hemoglobin | - |
dc.subject.keywordAuthor | Insulin resistance | - |
dc.subject.keywordAuthor | Endothelial function | - |
dc.subject.keywordPlus | ASSESSING INSULIN SENSITIVITY | - |
dc.subject.keywordPlus | RECIPROCAL RELATIONSHIPS | - |
dc.subject.keywordPlus | CARDIOVASCULAR-DISEASE | - |
dc.subject.keywordPlus | GLUCOSE-TOLERANCE | - |
dc.subject.keywordPlus | STATIN THERAPY | - |
dc.subject.keywordPlus | ADIPONECTIN | - |
dc.subject.keywordPlus | ATORVASTATIN | - |
dc.subject.keywordPlus | SIMVASTATIN | - |
dc.subject.keywordPlus | RESISTANCE | - |
dc.subject.keywordPlus | RISK | - |
dc.relation.journalResearchArea | Cardiovascular System & Cardiology | - |
dc.relation.journalWebOfScienceCategory | Cardiac & Cardiovascular Systems | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
1342, Seongnam-daero, Sujeong-gu, Seongnam-si, Gyeonggi-do, Republic of Korea(13120)031-750-5114
COPYRIGHT 2020 Gachon University All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.